HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently

Vaccine ◽  
2009 ◽  
Vol 27 (48) ◽  
pp. 6739-6747 ◽  
Author(s):  
Venkatesh Prasanna Kashi ◽  
Rajesh Abraham Jacob ◽  
Siddhartha Paul ◽  
Kaustuv Nayak ◽  
Bhuthiah Satish ◽  
...  
2021 ◽  
Vol 10 (1) ◽  
pp. 06-13
Author(s):  
Viol Dhea Kharisma ◽  
Arif Nur Muhammad Ansori ◽  
Gabrielle Ann Villar Posa ◽  
Wahyu Choirur Rizky ◽  
Sofy Permana ◽  
...  

Acquired immune deficiency syndrome (AIDS) has been identified from US patients since 1981. AIDS is caused by infection with the human immunodeficiency virus type 1 (HIV-1) which is a retrovirus. HIV-1 gp120 can be recognized by the immune system because it is located outside the virion. The conserved region is identified in gp120, and it is recognized by an immune cell which then initiates specific immune responses, viral mutation escape, and increase vaccine protection coverage, a benefit derived from the conserved region-based vaccine design. However, previous researchers have little knowledge on this conserved region as a target for vaccine design. This paper explains how the conserved region of gp120 HIV-1 is a major target for vaccine design through a bioinformatics approach. The conserved region from gp120 was explored as a vaccine design target with a bioinformatics tool that consists of B-cell epitope mapping, vaccine properties, molecular docking, and dynamic simulation. The peptide vaccine candidate of B5 with the gp120 HIV-1 conserved region was found to provoke B-cell activation through a direct pathway, produce specific antibody, and increase protection from multi-strain viral infection.


Immunity ◽  
2004 ◽  
Vol 21 (5) ◽  
pp. 617-627 ◽  
Author(s):  
Ara G. Hovanessian ◽  
Jean-Paul Briand ◽  
Elias A. Said ◽  
Josette Svab ◽  
Stephane Ferris ◽  
...  

Animals ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 1344
Author(s):  
Marco A. Juárez-Estrada ◽  
Amanda Gayosso-Vázquez ◽  
Guillermo Tellez-Isaias ◽  
Rogelio A. Alonso-Morales

This study investigated protection against Eimeria tenella following the vaccination of chicks with 5.3 × 106 E. tenella whole-sporozoites emulsified in the nanoparticle adjuvant IMS 1313 N VG Montanide™ (EtSz-IMS1313). One-day-old specific pathogen-free (SPF) chicks were subcutaneously injected in the neck with EtSz-IMS1313 on the 1st and 10th days of age. Acquired immunity was assayed through a challenge with 3 × 104 homologous sporulated oocysts at 21 days of age. The anticoccidial index (ACI) calculated for every group showed the effectiveness of EtSz-IMS1313 as a vaccine with an ACI of 186; the mock-injected control showed an ACI of 18 and the unimmunized, challenged control showed an ACI of −28. In a comparison assay, antibodies from rabbits and SPF birds immunized with EtSz-IMS1313 recognized almost the same polypeptides in the blotting of E. tenella sporozoites and merozoites. However, rabbit antisera showed the clearest recognition pattern. Polypeptides of 120, 105, 94, 70, 38, and 19 kDa from both E. tenella life cycle stages were the most strongly recognized by both animal species. The E. tenella zoite-specific IgG antibodies from the rabbits demonstrated the feasibility for successful B cell antigen identification.


2017 ◽  
Vol 76 (3) ◽  
pp. e90-e92 ◽  
Author(s):  
M. Christian Tjiam ◽  
Mazmah A. Morshidi ◽  
Lucy Sariputra ◽  
Jeffrey N. Martin ◽  
Steven G. Deeks ◽  
...  

2012 ◽  
Vol 8 (10) ◽  
pp. 1425-1430 ◽  
Author(s):  
Gideon Goldstein ◽  
Eve Damiano ◽  
Mardik Donikyan ◽  
Malika Pasha ◽  
Erik Beckwith ◽  
...  

2003 ◽  
Vol 334 (1) ◽  
pp. 87-101 ◽  
Author(s):  
David Enshell-Seijffers ◽  
Dmitri Denisov ◽  
Bella Groisman ◽  
Larisa Smelyanski ◽  
Ronit Meyuhas ◽  
...  
Keyword(s):  
B Cell ◽  

Sign in / Sign up

Export Citation Format

Share Document